학술논문
Barnase-barstar Specific Interaction Regulates Car-T Cells Cytotoxic Activity toward Malignancy.
Document Type
Article
Author
Kalinin, R. S.; Shipunova, V. O.; Rubtsov, Y. P.; Ukrainskay, V. M.; Schulga, A.; Konovalova, E. V.; Volkov, D. V.; Yaroshevich, I. A.; Moysenovich, A. M.; Belogurov, A. A.; Telegin, G. B.; Chernov, A. S.; Maschan, M. A.; Terekhov, S. S.; Knorre, V. D.; Khurs, E.; Gnuchev, N. V.; Gabibov, A. G.; Deyev, S. M.
Source
Subject
*EPIDERMAL growth factor receptors
*TUMOR antigens
*THERAPEUTIC complications
*
*
Language
ISSN
1607-6729
Abstract
The development of CAR-T specific therapy made a revolution in modern oncology. Despite the pronounced therapeutic effects, this novel approach displayed several crucial limitations caused by the complications in pharmacokinetics and pharmacodynamics controls. The presence of the several severe medical complications of CAR-T therapy initiated a set of attempts aimed to regulate their activity in vivo. We propose to apply the barnase-barstar system to control the cytotoxic antitumor activity of CAR-T cells. To menage the regulation targeting effect of the system we propose to use barstar-modified CAR-T cells together with barnase-based molecules. Barnase was fused with designed ankyrin repeat proteins (DARPins) specific to tumor antigens HER2 (human epidermal growth factor receptor 2) The application of the system demonstrates the pronounced regulatory effects of CAR-T targeting. [ABSTRACT FROM AUTHOR]